Recent Financings of Private Companies (09/2010)
This article was originally published in Start Up
Executive Summary
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
You may also be interested in...
Cell/Gene Therapy Is Ripe For Real-World Data Given Length Of Follow-Up Required, Abernethy Says
The former principal deputy commissioner outlined what she sees as the future data requirements for real world evidence and why cell and gene therapy will lead the way.
China May Ease Data Transfer Rules But Regulatory Ambiguity Remains
China's latest proposed rules governing the overseas transfer of personal data may allow pharma, biotech and digital health companies to avoid regulatory security reviews and formal standard contracts, as well as personal information protection certification, but key definitions of “important data” and “negative list” items remain to be clarified.
Amgen’s Lumakras: FDA Flags ‘Marginal’ Efficacy Results, Potential Systemic Bias In Lung Cancer Trial
Company seeks conversion from accelerated to regular approval for the first KRAS G12C inhibitor on the market, but the agency is asking its Oncologic Drugs Advisory Committee whether the progression-free survival primary endpoint in the CodeBreaK 200 confirmatory trial can be reliably interpreted.